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A BST R A C T: Alzheimer’s disease (AD) is the most common form of dementia affecting
people over the age of 60, yet a detailed understanding of the molecular changes involved
in AD remains a significant challenge to modern medicine. The hallmarks of an AD brain
include the presence of senile plaques formed by a protein called amyloid-β (Aβ), along
with inflammation of the brain. Aβ self-associates to form clumps of protein called
“aggregates” which are known to be the primary toxic agents in AD pathology; however,
several other proteins have also been implicated in this pathology. One such protein called
progranulin (PGRN), which under normal physiological conditions plays a role in
inflammation, has been shown to be present at higher concentrations in many
neurodegenerative diseases including AD. The smaller fragments of PGRN are
proinflammatory proteins known as granulins (Grn) that, interestingly, have a molecular
structure similar to the one observed in Aβ aggregates. Due to this structural similarity and
the colocalization of PGRN and Aβ in an AD brain we are investigating the interaction
between the most common Grn, human Granulin-A (hGrn-A), and Aβ through several
biochemical methods as well as the structure of hGrn-A itself. These studies have led to
the discovery of a concentration-dependent change in conformational status of hGrn-A that
we believe has an effect upon interactions with Aβ aggregates. Our results indicate that
hGrn-A specifically interacts with Aβ in a concentration-dependent manner to effect both
inhibition as well as augmentation of aggregate formation. This unique modulation of Aβ
aggregate formation allows for an entirely new perspective on the mechanisms of AD
pathology, though more trials are required to further characterize these interactions.
K E Y T E R MS: Alzheimer’s disease, amyloid-beta, neuroinflammation, progranulin,
granulin
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C H A PT E R I

Description of the Problem
The most common form of dementia among the neurodegenerative diseases is
Alzheimer’s disease (AD), which is characterized by acute memory loss and cognitive
dysfunction in the elderly. The pathological hallmark of AD is the deposition of amyloid-β
(Aβ) peptide aggregates as senile plaques in the cortical regions of the brain. Aβ
aggregates are believed to be the main toxic agent in AD (1,2). Recently, mutations in the

GRN gene which codes for a protein called progranulin (PGRN) have been shown to lead
to changes in the regulation of PGRN in various neurodegenerative diseases including AD
(4,15-17). In AD, PGRN is upregulated in neuronal microglia surrounding the Aβ plaques
(4). PGRN is well known to play a role in wound healing and injury repairs (6-9).
Cleavage of PGRN by proteases such as elastases lead to smaller proteins called granulins

(Grn) (6,7). Interestingly, a comparison of one of the granulins, carp Grn-A, and Aβ
fibrillar structure reveal similarities ( Figure1).
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Both Aβ fibrils and carp Grn-A form parallel β-sheets. However, parallel β-sheets
in Aβ fibrils are held together by H-bonds while the same is replaced by conserved
disulfide bonds in Grn-A (8, 10). The formation of plaques and oligomers of Aβ by
aggregation is a nucleation-dependent process or, in other words, a structural template is
needed for Aβ to “stick to” each other. Sequence comparison of the two proteins by
BLAST did not yield significant similarities but did indicate potential interacting sites
( Figure2). The GxxxGxxxGxxxI amino acid pattern seen below is a motif remaining from
the transmembrane origin of Aβ. This motif is commonly observed in transmembrane
spanning domains and it has been established that the same motif forms a ‘groove’ in a βsheet arrangement, which in turn can function as molecular recognition site (19).
Considering the original conformation of Aβ monomers is a random coil with the
formation of aggregates requiring a nucleation event, a shift to a parallel β-sheet
conformation, hGrn-A with its covalent disulfide bond stabilized parallel β-sheet
conformation appears to be a candidate aiding in the shift of Aβ monomer to its pathogenic
conformation.

It is within this context that hGrn-A may play a role acting as a “seed” for the
nucleation of Aβ aggregates. In this work, I propose to explore the potential interactions of
Aβ and hGrn-A via biophysical and biochemical means such as thioflavin-T (ThT)
fluorescence assays, fluorescence anisotropy, and circular dichroism spectroscopy.

2

H Y P O T H ESIS: Considering the primary and secondary structural characteristics of GrnA and Aβ as well as the likely co-localization of these two proteins has lead to the
investigation of hGrn-A as a protein predicted to augment the formation of Aβ aggregates.
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C H A PT E R I I

L iterature Review
The aggregation of Aβ peptide is a process implicated in leading to
neurodegeneration in AD. AD is characterized by the progressive memory impairment,
disordered cognitive function, altered behavior, and a progressive decline in language
function in an individual (1). Two primary lesions are well characterized within cases of
AD, neurofibrillary tangles and neuritic plaques, formed by hyperphosphorylated Tau
protein and by Aβ peptide aggregates respectively (1,2). Aβ is generated by the cleavage of
a large transmembrane protein called APP sequentially by β- and γ-secretases (1,2). The
length of Aβ peptide varies between 37 and 43 amino acids in length; however, the most
common species are Aβ40 and 42, with the numbers indicating the quantity of amino acid
residues in each (1). Aβ42 seems to have stronger aggregation propensity and is known to
be a part of early pathogenic aggregates. Aβ is known to self-associate with a sigmoidal
growth curve of aggregation, beginning with a ‘lag phase’, then ‘growth phase’ and finally
‘stationary’ phase (1, Figure3). Nucleation takes place during the “lag” phase, during
which the random-coil conformation of native Aβ peptide rearranges into the repeating
parallel β-sheet conformation seen in Aβ fibrils (2,3,11). The “lag” phase can be removed
or reduced by introducing pre-formed aggregate “seeds” (3). Aβ aggregation is a
nucleation-dependent process resulting in the formation of both intermediate Aβ oligomers
and large, multimeric Aβ fibrils. An increasing body of evidence has lead to these
oligomers becoming known as the primary neurotoxic agents due to greater solubility in
comparison to fibrils, increasing their ability to interfere with neuronal function (2). Due to
Aβ aggregate formation being a nucleation-dependent process leading to self-association,
4

any process or mechanism to affect the nucleation could lead to theoretical formulation of
treatments for AD.

Progranulin (PGRN) is 593 amino acids in length comprised of 7.5 repeats of a
cysteine-rich granulin / epithelin motif (GEM) and has been implicated in the regulation of
development, tumorigenesis, wound healing, and inflammation (6-11). The initial interest
in PGRN in the context of neurodegenerative disorders came with the examination of
mutations in human chromosome 17 that lead to frontotemporal lobar degeneration
(FTLD) (4). The first genetic mutation linked to the incidence of FTLD was MAPT which
codes for a protein called Tau (as mentioned earlier, Tau forms neurofibrillary tangles in
AD); however, since mutations in this gene were not always present in cases of FTLD,
further examinations in these cases led to implication of mutations in the GRN gene which
codes for PGRN (4). Studies have discovered 68 pathogenic mutations in GRN to date,
5

second only to PS EN1 (a prominent AD gene) in the number of pathogenic mutants known
(http://www.molgen.ua.ac.be/FTD mutations). Following from this logic, studies have been
carried out to show whether detection of PGRN concentration levels in human plasma can
be used as a biomarker for GRN mutations (15-17). In cases that showed relatively low
expression of plasma PGRN was an indicator for a predisposition for AD along with FTLD
(17). The correlation of Aβ plaques with PGRN expression levels in a transgenic AD
mouse model suggests potential interactions between the two (4). Some other literature
demonstrate high expression of PGRN increasing neurite outgrowth, survival and allowing
neurons to resist apoptosis (12,13) suggesting the importance of PGRN in neuronal
survival and growth. Other research has shown that mutations that lead to down-regulation
of PGRN are dependable indicators of neurodegenerative disease (17). This has lead to an
increase in studies on PGRN and how it is related to AD on a molecular-level.
PGRN is cleaved through extracellular proteases, such as elastases, as part of a proinflammatory response by activated microglia to form smaller proteins known as granulins
(Grn) (6-10). Grns are known to be inflammatory in nature as opposed to PGRN being
anti-inflammatory (6,7). PGRN is cleaved to form several different Grns (hGrnA-hGrnF),
of which only two have well-formed structures in solution (hGrn-A and hGrn-C) (6,7).
hGrn-A is of particular interest due to its structure similarities with Aβ fibrils ( Figure1).
The repeating parallel β-sheet structure found within both of these proteins (7,8,11), the
area of possible interaction at the C-terminus ( Figure2) and correlation between PGRN and
Aβ plaques in an AD model system indicate hGrn-A to be a possible candidate for further
study. Because there is so little information about Grns, it is not known what their role may
be in AD or in other neurodegenerative disease; however, since their precursor protein has
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been correlated with AD plaques as well as with other neurodegenerative diseases, it seems
as though they might have a role in augmenting the early stages of aggregate formation
(“seeding”).
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C H A PT E R I I I

M ethods
M aterials. A plasmid containing hGrn-A gene as a fusion construct ( Figure4) was
obtained from Dr. Andrew Bateman, McGill University in Canada. This had been
subcloned in pET-32a(+) vector to be expressed as a thioredoxinA-hGrn-A (TrxA-hGrn-A)
fusion protein with an enterokinase (Enk) cleavage site ( Figure4). Synthetic Aβ peptide

used in my assays was obtained from Mayo Clinic, Rochester, MN, and purified using a
size-exclusion chromatography (SEC) column to remove any preformed aggregates.
Enzymes and buffers associated with restriction endonuclease cleavage were procured
from New England Biolabs. Recombinant enterokinase was obtained from Novagen, Inc.
SDS, bovine serum albumin (BSA), and thioflavin-T (ThT) were purchased from Sigma
Aldrich Inc (St. Louis, MO). All other chemicals were obtained from VWR Inc.
E xp ression of recombinant T rxA-h G rn-A fusion protein. Origami 2 (DE3)
competent cells, chosen for their cellular conditions that aid intracellular disulfide bond
formation, were used for transformation. In order to confirm insertion of plasmid,
restriction endonuclease digestion was carried out using the enzymes XhoI and NcoI and,
separately, with HindIII and NcoI. The restriction digestion was prepared by first making a
mixture with 10x bovine serum albumin (BSA) and 10x NEB4 Buffer diluted with water
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used as the stock solution. This mixture was used to prepare isolated plasmids for digestion
along with the enzymes listed above.
The digestion fragments showed products of 210bp and 190bp respectively on an
8% acrylamide gel stained with ethydium bromide, confirming the transformation of
competent cells. A 5mL culture was prepared containing LB broth with 12.5μg/mL
tetracycline, 50μg/mL streptomycin and 100μg/mL ampicillin present. This was incubated
overnight with shaking at 37°C after which 2mL of the culture is used to inoculate 1L of
LB broth with the same concentrations of antibiotics present. This was incubated until the
optical density reached 0.6 at which point the cells were induced with isopropyl β-D-1thiogalactopyranoside (IPTG) to a concentration of 0.4mM in solution. The induced
culture incubated with shaking at 37°C for 3h, after which the cells were centrifuged at
10,000rpm for 20min, the supernatant discarded and cells stored at -20°C.
Pu rification of h G rn-A fusion protein. Purification was performed following the
protocol as published (8). The stored pellet was resuspended in loading buffer (10mM
imidazole, 20mM tris, 300mM NaCl, 8M urea, pH 7.0) and sonicated, after adding
phenylmethylsulfonyl fluoride (PMSF) to a concentration of 0.2mM, in five cycles of 30
seconds, each with a 30 second interval period. The sample was centrifuged at 10,000
RPM for 20 minutes and the supernatant collected. The supernatant was loaded onto a NiNTA affinity column pre-equilibrated with loading buffer. Since the fusion protein
contains a His-tag ( Figure4), it was retained in the column. Washes of the column to
remove non-specific binding proteins was carried out using buffers with 50mM and
100mM imidazole before using an elution buffer of 400mM imidazole concentration. The
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sample was dialyzed against buffer (20mM tris, 150mM NaCl, 2mM CaCl2, pH 7.0) with a
1kDa MWCO membrane to remove imidazole.
C leavage of h G rn-A fusion protein. A rough concentration estimate was obtained
from UV-Vis spectra. 2.5mg of protein was incubated with 50U of enterokinase at 37°C
for 48h to cleave TrxA from hGrn-A. For early attempts at purification, the resulting
sample was run through a HiTrap 5mL desalting column to remove the urea and salt,
leaving the protein in buffer at pH 7.0, and the fractions were pooled and stored at -80°C
followed lyophilization overnight. However, in later attempts this desalting stage was
found to be an unnecessary obstacle to both efficient use of time and protein yield and was
thus removed.
Isolation of h G rn-A . The sample was loaded onto an equilibrated LiChrospher
100 C-18 reverse-phase HPLC column (Merck KGaA, Darmstadt, Germany) mounted on
an AKTA FPLC apparatus (GE Healthcare, Buckinghamshire) with a flow restrictor
attachment. Proteins were then eluted utilizing a gradient of 20-100% acetonitrile (ACN)
concentration with hGrn-A expected and observed to elute at approximately 35%. The
fractions that displayed a peak according to the absorbance measured at 280nm were
collected and SDS-PAGE electrophoresis along with MALDI-TOF mass spectrometry
were performed to confirm purity of hGrn-A. The samples contained isolated hGrn-A were
to be pooled and lyophilized.
F luorescence spect roscopy. Intrinsic fluorescence: The capability and extent of
hGrn-A and Aβ monomer was examined through titrations maintaining a constant
concentration of Aβ monomer at 2.0μM and an increasing concentration of hGrn-A from
0.0 μM to 8.0 μM. This was also done using Aβ oligomer.
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ThT kinetics: Various molar ratios between Aβ peptide and hGrn-A were incubated
together at 37°C. Starting with the 0h measurement at the beginning of the incubation, the
kinetics were measured through the use of a fluorescence spectrophotometer set to 452nm
for excitation and collecting at 482nm for emissions. ThT binds with aggregated Aβ to
form a complex that excites and emits at the given wavelengths. It is in this way that the
control curve of Aβ peptide without hGrn-A present were to be compared to the kinetic
readings given from the incubations with both Aβ peptide and hGrn-A to show whether Aβ
is forming aggregates or not.

Anisotropy: The inherent fluorophores Tyrosine and Tryptophan found in Aβ and
hGrn-A respectively were initially used for detection. Meaningful data was not gathered
from this, due to the low relative intensity of these fluorophores. Thus mutant Aβ peptide
strains were used for their increased fluorescent ability. Two Aβ mutants were available: a
single amino acid mutant with phenylalanine at position 19 replaced with tryptophan
(F19W) and an N-terminus dansylated Aβ42 (AβDan). Through anisotropy, if or how Aβ
peptide and hGrn-A interact and at what comparative stoichiometric ratios they interact
may be shown.
AβDan oligomer generation. Oligomeric AβDan was generated by following
previously reported methods (18). 50μM AβDan was incubated with 5mM lauric acid at
37°C for 48h with the resulting sample then fractionated through size exclusion
chromatography. Relevant fractions were collected and stored for further use.
Polyacrylamide gel elect rophoresis (PA G E) and immunoblotting. Samples
were dissolved in 1x Laemmli loading buffer containing 1%SDS and applied with heating
to either hand-made 12% polyacrylamide gels or to 4-15% Mini-PROTEAN TGX gels
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(BioRad) also containing 1% SDS. These gels were resolved in Laemmli running buffer
with 0.1% SDS. Novex Sharp Protein Standards (Invitrogen) were run in parallel for use as
MW markers. Immunoblotting was carried out through the use of a polyclonal antibody for
hGrn-C (Alexis Biochemical). A monoclonal antibody was employed for detection of Aβ
(Mayo Clinic), thus allowing for detection of hGrn-A Aβ association by running parallel
SDS-PAGE electrophoresis gels and blotting them each with one of the aforementioned
antibodies.
C ircula r dich roism (C D) spectroscopy. Samples were placed in 0.1 cm pathlength quartz cuvette (Hellma) and far-UV spectra were obtained with a Jasco J-815
spectropolarimeter (Jasco Inc, Easton, MD). These were monitored in continuous scan
mode (260-190nm) with parameters set for 50 nm/min acquisition with 8 s response time,
1 nm bandwidth and 0.1 nm data pitch. The temperature interval measurement mode was
used for simple buffer and 1% SDS temperature melts of hGrn-A with similar parameters
set as well as a 10°C interval between each scan (10°C to 90°C range).
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C H A PT E R I V

Results
I: E xp ression and Purification of h G rn-A
For the recombinant expression, positive results in regards to transformation of
Origami 2 (DE3) cells were acquired. A confirmation of the hGrn-A plasmid being
inserted into the vector can be seen in Figure 5 below. Group I and II on the gel denote
different pairs of endonucleases utilized, XhoI with NcoI (~210bp) and HindIII with NcoI
(~190bp) respectively.

13

The ability to overexpress the desired fusion protein through IPTG induction was
then confirmed via SDS-PAGE for every purification. Results from three colonies are
shown ( Figure6). There was much more protein present in the induced fractions, as
expected, and it was also observed that the fusion protein is found in the supernatant after
centrifugation.

L a rge scale production and purification of h G rn-A fusion protein
Following these initial stages, 1L cultures of transformed Origami 2 (DE3) cells
were produced for large scale expression of fusion protein. These cells were then
centrifuged, resuspended in 20 to 30 mL of Ni affinity column loading buffer, and stored at
-20 ºC. When removed from storage, lysed, centrifuged, and loaded onto the Ni affinity
column a slight loss of protein was observed in column washes with lower concentrations
14

of imidazole, however the loss was negligible ( Figure7a). From each isolation of fusion
protein by Ni affinity a quantity greater than 12mg of fusion protein was obtained, with
some isolations yielding as much as 20mg. After this, the cleavage of the fusion protein
would be carried out and confirmed by SDS-PAGE as seen in Figure 7b.

The successfully cleaved sample would then be injected into a RP-HPLC column
and the peaks characterized; the data associated with this can be seen in Figure 8. Peak I
appears to be where we find our isolated hGrn-A fragment. This was confirmed by
MALDI-TOF mass spectrometry as seen in Figure 9.

15

16

I I: Interactions between Aβ and hGrn-A
After standardizing the production, isolation, cleavage, and purification of hGrn-A,
interaction studies assessing the ability of hGrn-A to bind to Aβ42 monomer and the
effects of hGrn-A on Aβ42 fibril formation began. For examining the ability of hGrn-A to
bind Aβ42, detection sensitivity was augmented through use of AβDan for its increased
quantum yield. The concentration of AβDan was held at a constant 2.0uM as the
concentration of hGrn-A was increased from 0.0µM to 8.0µM ( Figure10a). A binding
assay was also carried out using AβDan oligomers generated as seen in Figure 10b. BSA
was used as the control binding protein.
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Alongside this experiment, we also measured the formation of Aβ aggregates in the
presence of hGrn-A through measuring ThT kinetics over time ( Figure11). As can be seen,
the amount of aggregation apparent was far less in the presence of even a 1:10 molar ratio
of hGrn-A to Aβ. There is also a trend of decreased inhibition at higher concentrations of
hGrn-A ( Figure11b).
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I I I: C ha racterization of h G rn-A Conformation
Due to the
unexpected finding
that hGrn-A inhibited
formation of
aggregates rather than
augmenting
formation, the
structure of hGrn-A in
solution was
examined more
closely. This began
with using far-UV CD
spectrometry to
observe the native
structure of hGrn-A in solution at 20.0µM and carrying out a serial dilution ( Figure12). As
seen below, this lead to the discovery that hGrn-A shows a maximum at 233nm and a
minimum at 204nm when in solution, with the maximum diminishing as the concentration
is decreased.
This decrease in the maximum was plotted and fitted to a monomer-dimer
equilibrium model equation with a resulting dissociation constant (Kd) of 2.95 ± 0.56µM.
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Another structural assay used was a temperature melt in the CD, where the
temperature of a 15.0µM sample of hGrn-A was heated in 10ºC increments from 10ºC to
90ºC ( Figure12). Here we saw the same decrease in the maximum at 233 nm as we saw in
Figure 11a, yet we also saw an isosbestic point at approximately 210 nm indicating a shift
between two discrete conformations.
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C H A PT E R V

Discussion
The first stage of this series of experiments, the expression and purification of
hGrn-A, has been successfully standardized. Still, there were questions resulting from first
stage data that were inconsistent with expectations, namely concerning the appearance of a
cleavage product of approximately 16kDa. Since this product was not seen in fractions
containing hGrn-A after HPLC it did not gain relevance until we began to examine the
structure of hGrn-A.
The second stage of the experiment led to some more surprising results. Instead of
hGrn-A acting as a seed for Aβ aggregate formation, a decrease in aggregate formation
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greater than 60% was observed at low concentrations of hGrn-A. This decrease in
aggregate formation was not uniform. Instead, maximum inhibition was at approximately
8.0µM, with higher concentrations (20.0µM, 40.0µM) showing less inhibition ( Figure11).
From this, as well as from the results of the binding assays, we can state that hGrn-A binds
to monomeric Aβ which in turn influences the formation of large Aβ aggregates in an
inhibitory manner ( Figure10a, Figure14). In the second data set shown in Figure 10b, the
binding of oligomeric Aβ to hGrn-A seems to be of a similar magnitude as seen with
monomeric Aβ. We have attempted to characterize the effect of this interaction through
ThT fluorescence as well as through anisotropy yet all trials have been inconsistent in their
results. Similarly, characterization of binding through anisotropy for both oligomers and
monomers was attempted but gave no conclusive results due to issues specific to
anisotropy.
Because of the decreased inhibition at higher concentrations shown in Figure 11b
along with the opposite effect than expected being displayed (inhibition rather than
augmentation), we looked more closely at the conformational status of hGrn-A through CD
spectroscopy. This resulted in our finding that hGrn-A is of a polyproline type-II helix
conformation when in solution ( Figure12, Figure13), as opposed to the parallel β-sheet
structure seen in carp Grn-A ( Figure1a). This conformation was concentration-dependent
as indicated through the loss of ellipticity at the 233nm maximum ( Figure12a). Since some
of the results in the initial hGrn-A purification stages indicated the formation of a possible
hGrn-A dimer, we used a monomer-dimer equilibrium model to fit the change in molar
ellipticity at 233nm with a resulting dissociation constant (Kd) of 2.95 ± 0.56µM. The
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isoasbestic point seen in both Figure 12 (~222nm) and Figure 13 (~210nm) further
indicates the presence of a shift between two discrete conformations.
It is difficult at this point to speak directly as to the nature of interactions between
hGrn-A and Aβ. The binding data would be much more reliable if verified through
immunoblot or anisotropy. Attempts to use polyclonal hGrn-C antibody for detection
showed only the fusion protein, never the cleaved product, and we are awaiting
maintenance to repair the fluorescence spectrophotometer for anisotropy. Future
experiments will work to differentially characterize interactions between hGrn-A with Aβ
aggregate products (oligomers and fibrils) through anisotropy as well as through CD.
There are many improvements and modifications that could and will likely be
employed to gather more results and increase throughput. The recombinant expression
could be modified to allow for cleavage of the histidine tag from hGrn-A, a construct for
which has already been produced for our lab by researchers at Florida State University, but
we have yet to achieve expression after several attempts in various cell lines. Also, a larger
quantity of protein could be cleaved through the use of a different enzymatic site, such as
thrombin, instead of enterokinase in the vector. Enterokinase is limiting in the quanity in
enzyme units required to cleave per mg of protein, the time it requires for efficient
cleavage, and the financial cost per enzyme unit. We have had the hGrn-A construct added
to a pET-15b plasmid to utilize a thrombin cleavage site in this vector, yet once again we
have never been able to express this protein after several attempts in various cell lines.
Another point we can modify in the recombinant expression is the protein’s
sequence in order to disrupt its native conformation in solution, which we have done
through modifying the proline at position 43 to a leucine (P43L) within a pET-32a vector.
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Through purifying this mutant and carrying out the same structural characterization as seen
in Figures 12 and 13, we would expect to see a different conformation and a different
effect upon Aβ aggregation.
With the structure of hGrn-A becoming understood more fully, we have a new
class of proteins that continues to be examined for their interactions in the etiology of
Alzheimer’s disease. Already there are many labs beginning in vivo studies in regards to
the Grn precursor protein, PGRN. Once our lab finds a functional method of increasing the
yield of pure hGrn-A, collaborations for production of monoclonal antibodies and a more
comprehensive examination of its interactions with Aβ will hopefully supply a useful
avenue for treatment of AD.
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